Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 1/20 | 0.40 |
| ▸ | NR3C1 | P04150 | 5/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.35 |
| ▸ | PLAU | P00749 | 1/20 | 0.35 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | HPGD | P15428 | 3/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL91154 | 0.81 | SMN1; SMN2 (0.48) | TDP1KDM4EALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL91228 | 0.81 | PKM (0.47) | ARNR3C1TDP1KDM4EALDH1A1 | |
| SCHEMBL16808239 | 0.79 | AR (0.38) | ARNR3C1FFAR1TDP1KDM4E | |
| SCHEMBL2037172 | 0.77 | HPGD (0.43) | ARFFAR1TDP1KDM4EALDH1A1 | |
| SCHEMBL12187855 | 0.77 | F2 (0.43) | ARFFAR1TDP1KDM4EALDH1A1 | |
| SCHEMBL91350 | 0.77 | F2 (0.67) | F2PLAUST14 | |
| SCHEMBL8272350 | 0.76 | MAPT (0.43) | TDP1ALDH1A1CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL27938601 | 0.76 | HPGD (0.48) | TDP1KDM4EALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL10730804 | 0.75 | F2 (0.41) | ARFFAR1TDP1KDM4EALDH1A1 | |
| SCHEMBL10760645 | 0.75 | HPGD (0.41) | ARFFAR1TDP1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181298-B2 | Intermediates for macrocyclic compounds | OCERA THERAPEUTICS, INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-20120226066-A1 | PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | MARSAULT ERIC (CA) | 2012-09-06 | — | — | US | disclosed |
| US-20120226067-A1 | PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | MARSAULT ERIC (CA) | 2012-09-06 | — | — | US | disclosed |
| US-20120226072-A1 | PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | MARSAULT ERIC (CA) | 2012-09-06 | — | — | US | disclosed |
| US-20120165566-A1 | PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | MARSAULT ERIC (CA) | 2012-06-28 | — | — | US | disclosed |
| US-20090240027-A1 | INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | TRANZYME PHARMA INC. | 2009-09-24 | — | — | US | disclosed |
| US-7521420-B2 | Macrocyclic antagonists of the motilin receptor | TRANZYME PHARMA, INC. (CA) | 2009-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165566-A1 | PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | MLNR, CHRM2, CHRM1 | AR 1493/4885NR3C1 1634/4885FFAR1 161/4885 |
| US-20120226066-A1 | PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | MLNR, CHRM2, CHRM1 | AR 1493/4885NR3C1 1634/4885FFAR1 161/4885 |
| US-20090240027-A1 | INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | MLNR, CCKAR, CHRM2 | AR 1359/4885NR3C1 1611/4885FFAR1 132/4885 |
| US-20120226067-A1 | PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | MLNR, CHRM2, CCKAR | AR 1482/4885NR3C1 1775/4885FFAR1 172/4885 |
| US-20120226072-A1 | PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | MLNR, CHRM2, CHRM1 | AR 1493/4885NR3C1 1634/4885FFAR1 161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.